Syndax Pharmaceuticals, Inc.
SNDX
$24.01
$0.512.15%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 589.36% | 538.71% | 1,866.34% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 628.88% | 597.19% | 2,133.71% | -- | -- |
| Cost of Revenue | 9.75% | 8.23% | 41.19% | 44.88% | 44.20% |
| Gross Profit | 80.58% | 51.13% | 11.36% | -10.98% | -25.84% |
| SG&A Expenses | 48.61% | 58.30% | 67.08% | 78.49% | 81.07% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.60% | 24.11% | 43.16% | 47.16% | 58.14% |
| Operating Income | 19.63% | 4.44% | -17.75% | -30.56% | -47.84% |
| Income Before Tax | 10.42% | -4.99% | -26.96% | -37.76% | -52.40% |
| Income Tax Expenses | -33.33% | -- | -- | -- | -- |
| Earnings from Continuing Operations | 10.46% | -4.89% | -26.85% | -37.64% | -52.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 10.46% | -4.89% | -26.85% | -37.64% | -52.25% |
| EBIT | 19.63% | 4.44% | -17.75% | -30.56% | -47.84% |
| EBITDA | 19.63% | 4.44% | -17.75% | -30.57% | -47.85% |
| EPS Basic | 11.52% | 0.45% | -15.38% | -19.97% | -25.83% |
| Normalized Basic EPS | 11.48% | 0.36% | -15.48% | -20.08% | -25.94% |
| EPS Diluted | 11.58% | 0.64% | -15.15% | -19.83% | -25.70% |
| Normalized Diluted EPS | 11.48% | 0.36% | -15.48% | -20.08% | -25.94% |
| Average Basic Shares Outstanding | 1.27% | 5.02% | 9.87% | 15.29% | 21.41% |
| Average Diluted Shares Outstanding | 1.27% | 5.02% | 9.87% | 15.29% | 21.41% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |